Home
Clinical Trials
A Trial to Evaluate the Effic...

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Last Updated: 2025-02-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

14727 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-17

Study Completion Date

2023-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

NCT04605159

Respiratory Syncytial Virus Infections

TERMINATED PHASE3

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440

Respiratory Syncytial Virus Infections

COMPLETED PHASE3

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391

Respiratory Syncytial Virus Infections

TERMINATED PHASE3

A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.

NCT06955728

RSV Infections RSV Immunisation Preterm Labour

NOT_YET_RECRUITING PHASE4

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056

Respiratory Syncytial Virus Infections

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy, safety, and immunogenicity of RSVpreF or placebo (1:1 randomization) in infants born to healthy women vaccinated during pregnancy, as well as the safety and immunogenicity in the pregnant women. This will be a global study which will span multiple RSV seasons.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

This is a double-blinded, placebo-controlled study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RSVpreF vaccine

RSVpreF

Group Type EXPERIMENTAL

RSVpreF

Intervention Type BIOLOGICAL

RSV vaccine (RSVpreF)

Placebo dose

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RSVpreF

RSV vaccine (RSVpreF)

Intervention Type BIOLOGICAL

Placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy women ≤49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.
* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
* Receiving prenatal standard of care based on country requirements.
* Had a fetal anomaly ultrasound examination performed at ≥18 weeks of pregnancy with no significant fetal abnormalities observed.
* Determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study.
* Documented negative HIV antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy and prior to randomization (Visit 1).
* Intention to deliver at a hospital or birthing facility where study procedures can be obtained.
* Expected to be available for the duration of the study and can be contacted by telephone during study participation.
* Participant is willing to give informed consent for her infant to participate in the study.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol OR If the maternal participant is illiterate, a thumbprinted informed consent must be obtained, which must be signed and dated by an impartial witness who was present throughout the entire informed consent process confirming that the maternal participant has been informed of all pertinent aspects of the study.

* Evidence of a signed and dated ICD signed by the parent(s)/legal guardian(s) OR If the infant participant's maternal participant/parent(s)/legal guardian(s) is illiterate, a thumbprinted informed consent must have been obtained, which must have been signed and dated by an impartial witness who was present throughout the entire informed consent process confirming that the maternal participant/parent(s)/legal guardian(s) has been informed of all pertinent aspects of the study for herself (maternal participant) and her fetus/infant prior to taking part in the study.
* Parent(s)/legal guardian(s) willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

* Prepregnancy body mass index (BMI) of \>40 kg/m2. If prepregnancy BMI is not available, the BMI at the time of the first obstetric visit during the current pregnancy may be used.
* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product or any related vaccine.
* Current pregnancy resulting from in vitro fertilization.
* Current pregnancy complications or abnormalities at the time of consent that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:

* Preeclampsia, eclampsia, or uncontrolled gestational hypertension.
* Placental abnormality.
* Polyhydramnios or oligohydramnios.
* Significant bleeding or blood clotting disorder.
* Endocrine disorders, including untreated hyperthyroidism or untreated hypothyroidism. This also includes disorders of glucose intolerance (eg, diabetes mellitus type 1 or 2) antedating pregnancy or occurring during pregnancy if uncontrolled at the time of consent.
* Any signs of premature labor with the current pregnancy or having ongoing intervention (medical/surgical) in the current pregnancy to prevent preterm birth.
* Prior pregnancy complications or abnormalities at the time of consent, based on the investigator's judgment, that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:

* Prior preterm delivery ≤34 weeks' gestation.
* Prior stillbirth or neonatal death.
* Previous infant with a known genetic disorder or significant congenital anomaly.
* Major illness of the maternal participant or conditions of the fetus that, in the investigator's judgment, will substantially increase the risk associated with the maternal or infant participant's participation in, and completion of, the study or could preclude the evaluation of the maternal participant's response (includes positive serologic testing for regional endemic conditions assessed during routine maternal care, as per local standards of care and obstetric recommendations).
* Congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other illness requiring chronic treatment with known immunosuppressant medications, including monoclonal antibodies, within the year prior to enrollment.
* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
* Participation in other studies involving investigational drug(s) within 28 days prior to consent and/or during study participation.
* Receipt of monoclonal antibodies within the year prior to enrollment or the use of systemic corticosteroids for \>14 days within 28 days prior to study enrollment. Permitted treatments include the receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies, prednisone doses of \<20 mg/day for ≤14 days and, inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids.
* Current alcohol abuse or illicit drug use. Note: Marijuana use is not considered an exclusion criterion for the study when elicited in participant screening, though it may be considered illicit in some locales.
* Receipt of blood or plasma products or immunoglobulin (Ig), from 60 days before investigational product administration, or planned receipt through delivery, with 1 exception, Rho(D) immune globulin (eg, RhoGAM), which can be given at any time.
* Previous vaccination with any licensed or investigational RSV vaccine or planned. Note: Licensed COVID-19 vaccines or COVID-19 vaccines authorized for temporary or emergency use will not be prohibited during the course of this study.
* Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
* Participants who are breastfeeding at the time of enrollment.

o Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

Minimum Eligible Age

0 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Partners, LLC

North Chesterfield, Virginia, United States

Site Status

Central Research Associates, Inc.

Birmingham, Alabama, United States

Site Status

Endocrinology and Internal Medicine Associates, PC

Birmingham, Alabama, United States

Site Status

OB/GYN Associates of Alabama, PC

Birmingham, Alabama, United States

Site Status

Sharp and Stone OB/GYN PC

Birmingham, Alabama, United States

Site Status

St Vincent's Hospital

Birmingham, Alabama, United States

Site Status

Children's of Alabama

Birmingham, Alabama, United States

Site Status

UAB Women & Infants Center - UAB Medicine

Birmingham, Alabama, United States

Site Status

University of Alabama at Birmingham/Center for Women's Reproductive Health

Birmingham, Alabama, United States

Site Status

Cullman Clinical Research, Inc

Cullman, Alabama, United States

Site Status

Cullman Primary Care, PC

Cullman, Alabama, United States

Site Status

Cullman Regional

Cullman, Alabama, United States

Site Status

University of South Alabama Children's and Women's Hospital

Mobile, Alabama, United States

Site Status

USA Health Strada Patient Care Center

Mobile, Alabama, United States

Site Status

Springhill Medical Center

Mobile, Alabama, United States

Site Status

Velocity Clinical Research, Gulfport

Mobile, Alabama, United States

Site Status

Velocity Clinical Research - Pheonix

Phoenix, Arizona, United States

Site Status

Valleywise Comprehensive Health Center Women's Clinic

Phoenix, Arizona, United States

Site Status

Valleywise Health Medical Center

Phoenix, Arizona, United States

Site Status

Mesquite Pediatrics

Tucson, Arizona, United States

Site Status

Watching Over Mothers and Babies

Tucson, Arizona, United States

Site Status

Banner University Medical Center

Tucson, Arizona, United States

Site Status

University of Arizona

Tucson, Arizona, United States

Site Status

Banner University Medical Center ( North Campus )

Tucson, Arizona, United States

Site Status

St. Bernards Medical Center

Jonesboro, Arkansas, United States

Site Status

St. Bernards OBGYN Associates

Jonesboro, Arkansas, United States

Site Status

The Children's Clinic of Jonesboro, P.A.

Jonesboro, Arkansas, United States

Site Status

The Children's Clinic of Jonesboro, PA

Jonesboro, Arkansas, United States

Site Status

Century Research Institute

Bellflower, California, United States

Site Status

Chowchilla Medical Center

Chowchilla, California, United States

Site Status

Loma Linda University Pediatric Clinic - Highland

Highland, California, United States

Site Status

Century Research Institute

Huntington Park, California, United States

Site Status

Matrix Clinical Research

Huntington Park, California, United States

Site Status

Chemidox Clinical Trials

Lancaster, California, United States

Site Status

Leonard S. Kurian, M.D., A Medical Corporation

Lancaster, California, United States

Site Status

Women & Infants Pavilion, Antelope Valley Hospital

Lancaster, California, United States

Site Status

Loma Linda University Adventist Health Sciences Center

Loma Linda, California, United States

Site Status

Loma Linda University Faculty Medical Clinics

Loma Linda, California, United States

Site Status

Loma Linda University Pediatric Clinics

Loma Linda, California, United States

Site Status

Loma Linda Unversity Children's Hospital

Loma Linda, California, United States

Site Status

Long Beach Clinical Trials

Long Beach, California, United States

Site Status

Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status